Arcutis Biotherapeutics, Inc.
ARQT
$22.91
$0.673.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 134.75% | 146.64% | 36.61% | -132.30% | 74.03% |
| Total Depreciation and Amortization | 0.18% | 37.07% | -86.91% | 900.64% | -75.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.28% | -4.25% | 15.56% | -18.23% | 20.38% |
| Change in Net Operating Assets | 88.34% | -488.92% | 128.99% | -1,028.72% | 58.81% |
| Cash from Operations | 1,592.87% | -641.36% | 101.07% | -3,961.50% | 97.84% |
| Capital Expenditure | -- | 100.00% | 87.17% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.38% | -244.26% | 41.62% | -64.57% | -58.93% |
| Cash from Investing | -35.38% | -244.91% | 48.28% | -66.31% | -58.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 152.17% | 6.96% | 249.37% | -84.74% | 557.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 152.17% | 6.96% | 249.37% | 100.41% | -24,823.60% |
| Foreign Exchange rate Adjustments | 162.11% | -147.50% | 4,900.00% | 101.71% | -338.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.56% | -232.56% | 206.01% | 71.30% | -225.57% |